Hydroxyurea for sickle-cell anaemia in Africa: Mind the gap

The Lancet Global Health

Volumn 3, Issue 3, 2015, Pages e124-e125

  Obaro, Stephen K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; MEASLES VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; RUBELLA VACCINE; ANTISICKLING AGENT;

AFRICA; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HUMAN; INFECTION RISK; MEMORY T LYMPHOCYTE; NEUTROPENIA; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKLE CELL ANEMIA; TRANSCRANIAL DOPPLER; ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; INFANT; PRESCHOOL CHILD;

ADOLESCENT; AFRICA; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; HYDROXYUREA; INFANT;

EID: 84925232855     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70371-7     Document Type: Note

References (5)

1. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. Lancet Glob Health 2014, 2:e80-89.
2. Successful outcome prompts early end to sickle cell anemia clinical trial (accessed Nov 24, 2014). http://medicalxpress.com/news/2014-11-successful-outcome-prompts-arly-sickle.html.
3. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011, 377:1663-1672.
4. Lederman HM, Connolly MA, Kalpatthi R, et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics 2014, 134:686-695.
5. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992, 79:2555-2565.